TrommTimes

Random Musings and News

, ,

When States Legalize Cannabis, Drugmakers Feel It

Does Lobbying Explain Why Washington Won’t?

A short briefing on the 2022 pharma-stock study, later substitution research, and what federal lobbying data actually show.

When states legalize marijuana, investors treat it as bad news for conventional drugmakers. That was the core finding of a 2022 PLOS ONE paper by economists at Cal Poly and the University of New Mexico. Using stock returns and sales data for hundreds of pharmaceutical firms from 1996 to 2019, they found returns were about 1.5 to 2 percent lower ten days after a state medical or recreational legalization event. They estimated investors priced in roughly $3 billion in lost annual sales per event and about $9.8 billion in lost market value across listed firms.

The authors were careful about what that meant. The industry was not shrinking. Returns still rose after legalization; they just rose less than markets had expected. Recreational laws produced a larger implied sales hit than medical laws. Generic manufacturers saw a bigger percentage drop; branded firms lost more in dollars because they are larger. Cannabis, they argued, behaves like a generic competitor that can enter many drug classes at once rather than one narrow indication.

More -->

Comments

Leave a Reply